journals pharmaceutical-technology-europe-1 
STAT
MAY 10, 2023
A new study in the New England Journal of Medicine presents a simple treatment option for peanut allergies in kids from 1 to 3 years of age: a skin patch. In the study, published Wednesday, French pharmaceutical company DBV Technologies and a group of investigators from across the U.S.,
European Pharmaceutical Review
DECEMBER 19, 2022
1 The resulting weakness can lead to twitching, cramps, pain, and joint and movement problems. 1 Types of NMD include muscular dystrophies, inflammatory myopathies and motor neurone diseases, such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) among others. Journal of Neuromuscular Diseases.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
NOVEMBER 24, 2020
A study in the British Journal of Surgery estimated that globally, 28 million procedures would be cancelled or postponed during the peak 12 weeks of COVID-19 disruption. Pharmaceutical companies cannot address this challenge alone. The conclusion is that backlog clearance will extend into 2021. “It
Pharmaceutical Technology
AUGUST 11, 2022
CO 2 e kg) (Figure 1). One dose from a DPI leads to only 4% of the emissions of a dose from a pMDI (Figure 1). A study published in the British Medical Journal (BMJ) monitored, over the course of a year, the effect of transitioning patients from their preexisting asthma treatment plan to DPIs.
pharmaphorum
JANUARY 19, 2023
It was a unique event, at which leaders from across the pharmaceutical pipeline addressed the needs of the industry, shared their own insights, and tackled debates on the crucial topics that influence the future of patient outcomes. Where we are today is probably the least resilient system in Europe.”
pharmaphorum
MARCH 16, 2022
Part 1 of this article discussed the massive disruptions to medical events caused by the COVID-19 pandemic and how attendees’ preferences have shifted as things have shaken out. You can read part 1 here. In the pharmaceutical industry digital marketing is nothing new, but in the context of onsite-and-online events it is.
European Pharmaceutical Review
DECEMBER 15, 2022
1–3 This broad class of serotonergic agents, such as psilocybin, can produce changes in sensory perception, mood and thought processes. As late-stage development continues, COMPASS Pathways is running a rigorous, Phase III clinical development programme of its psilocybin therapy for TRD across Europe and North America.
Expert insights. Personalized for you.
245 
Let's personalize your content